Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issue of Cancer Cell, Junttila et al. show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which explains why trastuzumab is ineffective in some tumors
Contains fulltext : 172842.pdf (publisher's version ) (Open Access)Compensatory me...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-pos...
Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issu...
Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite i...
SummaryHerceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and benefits p...
AbstractWomen with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy ...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
Trastuzumab resistance remains a challenge in the treatment of the 15-20% of breast cancers which ar...
AbstractThe ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy i...
[[abstract]]The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic effica...
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined a...
Epidermal growth factor receptor-2 (ErbB-2/HER2) is a potent breast oncogene that has been shown to ...
SummaryUnsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, resistance t...
Although trastuzumab has been successfully used in patients with HER2-overexpressing metastatic brea...
Contains fulltext : 172842.pdf (publisher's version ) (Open Access)Compensatory me...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-pos...
Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issu...
Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite i...
SummaryHerceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and benefits p...
AbstractWomen with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy ...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
Trastuzumab resistance remains a challenge in the treatment of the 15-20% of breast cancers which ar...
AbstractThe ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy i...
[[abstract]]The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic effica...
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined a...
Epidermal growth factor receptor-2 (ErbB-2/HER2) is a potent breast oncogene that has been shown to ...
SummaryUnsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, resistance t...
Although trastuzumab has been successfully used in patients with HER2-overexpressing metastatic brea...
Contains fulltext : 172842.pdf (publisher's version ) (Open Access)Compensatory me...
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kina...
The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-pos...
DOI
Add to ORKG